<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:department>Basic Medical Sciences</gtr:department><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/466CC49E-5B81-4CEB-8CF2-5F105D12C677"><gtr:id>466CC49E-5B81-4CEB-8CF2-5F105D12C677</gtr:id><gtr:firstName>Larry Mark</gtr:firstName><gtr:surname>Fisher</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FD014484%2F1"><gtr:id>915C8942-76CB-46A1-B370-6A161221E092</gtr:id><gtr:title>Recognition, opening and stabilization of DNA gates by topo IV the chromosome decatenase</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/D014484/1</gtr:grantReference><gtr:abstractText>The enzyme topo IV mediates the untangling of bacterial chromosomes prior to their segregation at cell division. Topo IV crosses one DNA helix through another allowing the separation of topologically interlocked chromosomes. It does this by an unusual mechanism: it makes a transient double-stranded DNA break (often called a 'gate') in one molecule through which the second DNA molecule is passed. Antibacterial quinolone drugs act by stabilising the open DNA gate which interferes with DNA replication causing cell death. Indeed, quinolones are now important drugs for the treatment of pneumonia and other infections caused by Streptococcus pneumoniae and othe Gram-positive pathogens. Despite it scientific interest and medical importance, little is known about the mechanism of topo IV and its drug interactions. In this study, we aim to examine (i)how S. pneumoniae topo IV recognises and opens potential gate sequences in DNA, and (ii) how quinolones stabilize such gates. The work will make use of synthetic and altered versions of a known topo IV gate which we identified on the S. pneumoniae chromosome. We shall also study the binding of mutant topo IV complexes to identify key protein residues that function to contact and open the DNA gate. Progress on topo IV and its DNA gates will advance fundamental understanding of chromosome biology and will aid the future design of more effective quinolones.</gtr:abstractText><gtr:technicalSummary>Topo IV, the chromosome decatenase, is the target of antimicrobial quinolones used against Streptococcus pneumoniae and other Gram-positive pathogens. The enzyme acts by introducing a transient double-strand DNA break into one DNA helix (the G or gate segment)through which is passed a second helix (the T or translocated segment). Antipneumococcal quinolones exert their cytotoxic effects by stabilising the open gate form of the G segment, the crucial first step in topo IV action. We aim to establish the DNA and protein determinants for recognition, opening and stabilization of the DNA gate formed by S. pneumoniae topo IV, the gram-positive topo IV paradigm. These studies will provide important new insights into the mechanism of topo IV and its interactions with quinolones.</gtr:technicalSummary><gtr:fund><gtr:end>2010-02-20</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2006-08-21</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>264537</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Media interest</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B8170B63-24B2-4D4B-9007-185D2257F6FD</gtr:id><gtr:impact>Article sparked emails on research

Work recognised</gtr:impact><gtr:outcomeId>5463c4c12302a3.78615125</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.rsc.org/chemistrywork/News/July/09070901.asp</gtr:url><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media interest</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6B23529A-2791-49A3-90B0-A548AD23BBD5</gtr:id><gtr:impact>Work presented at World Conference of Scientific Journalists in Oxford and at briefing at the French Embassy, London

N/A</gtr:impact><gtr:outcomeId>5463c1778e2024.62508129</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The main impact of our work has been two-fold: academic and pharmaceutical. First, it has provided a breakthrough in understanding the mechanism of topoisomerase action and how quinolone drugs capture the enzyme-DNA complex to exert their antibacterial effects. Second, access to the crystal structures we have generated has provided key information to pharmaceutical companies in aiding their efforts to design new topoisomerase-targeting therapeutics including those that exploit novel binding sites on the enzyme-DNA complex. Our Nature paper resulting from this work has consequently been highly cited in the field.</gtr:description><gtr:firstYearOfImpact>2010</gtr:firstYearOfImpact><gtr:id>C6E55710-F018-4E8F-AC7C-311E453AB85F</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>5463c8dee4c317.91314043</gtr:outcomeId><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We have investigated the DNA sequence and structural determinants that govern formation of the quinolone-DNA cleavage complex of topoisomerase IV, the enzyme that mediates the unlinking and segregation of bacterial chromosomes. The main achievements were:

1. A novel DNA cleavage assay has been developed that allows the rapid identification of the DNA cleavage requirements. The assay will be widely applicable to all type II topoisomerases that act via a double-stranded DNA break.
2. By using the assay in concert with site-directed mutagenesis, we have for the first time established the DNA, drug and protein requirements for quinolone-induced DNA cleavage by topo IV (Arnoldi E, Pan X-S and Fisher LM (2013) Nucleic Acids Res 41, 9411-9424, 2013.
3. Using DNA recognition data and subunit domains generated during this study, we have solved the crystal structures of quinolone-DNA cleavage complexes of topo IV, the first for any type II topoisomerase (Laponogov I et al Nat Struct Mol Biol 16, 667, 2009). These structures provide a molecular insight into quinolone action and resistance and constitute a valuable framework for drug development</gtr:description><gtr:exploitationPathways>Our work provides the first crystal structures to reveal how quinolones-a clinically important group of antimicrobial agents- interact with their clinical target, the enzyme topoisomerase IV. These structural insights not only explain the mode of action of known drugs, but will guide attempts by pharmaceutical companies to develop new agents that act to circumvent resistance. These key structures have been deposited in the Protein Data Bank-entries 3FOE and 3FOF.</gtr:exploitationPathways><gtr:id>01B1BB61-1995-460E-A0E6-8B940F548CF3</gtr:id><gtr:outcomeId>5463a6f182b8f0.97798515</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Were able for the first time to produce highly active recombinant gyrase and topoisomerase IV from Streptococcus pneumoniae in quantity and of high quality.</gtr:description><gtr:id>A7DFE0C8-BB30-4281-A062-EA5E5187CE7E</gtr:id><gtr:impact>Supplied to a small biotech company engaged in the development of novel antimicrobial agents.</gtr:impact><gtr:outcomeId>5463c7ba6d2ea8.66419649</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Recombinant enzymes</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>76328C2C-CD87-4C28-8C8F-F338BEECC3FB</gtr:id><gtr:title>Functional determinants of gate-DNA selection and cleavage by bacterial type II topoisomerases.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/551bda1a8156f71fe66df1f07a3b1f0d"><gtr:id>551bda1a8156f71fe66df1f07a3b1f0d</gtr:id><gtr:otherNames>Arnoldi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>5463b2609521e4.58746972</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>073A38EB-42CF-4EB8-A6EC-ACD9F7F1D492</gtr:id><gtr:title>Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/757758d1cad053304eaebed51bf8f2d8"><gtr:id>757758d1cad053304eaebed51bf8f2d8</gtr:id><gtr:otherNames>Laponogov I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>5463af6dd10128.76203431</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/D014484/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>